JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCoy, K. L.
Right arrow Articles by Cabral, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCoy, K. L.
Right arrow Articles by Cabral, G. A.

Vol. 289, Issue 3, 1620-1625, June 1999

Cannabinoid Inhibition of the Processing of Intact Lysozyme by Macrophages: Evidence for CB2 Receptor Participation1

Kathleen L. McCoy, Marina Matveyeva, Steven J. Carlisle and Guy A. Cabral

Department of Microbiology and Immunology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia

Delta9-tetrahydrocannabinol (THC) impairs multiple immunological functions. The ability of a macrophage hybridoma to function as an antigen-presenting cell was examined by the stimulation of a soluble protein antigen-specific helper T cell hybridoma to secrete interleukin-2. THC exposure significantly reduced the T cell response to the native form of the antigen after a 24-h pretreatment of the macrophages with nanomolar drug concentrations. However, THC did not affect interleukin-2 production when the macrophages presented a synthetic peptide of the antigen to the T cells, suggesting that the drug may interfere with antigen processing, not peptide presentation. Cannabinoid inhibition of the T cell response to the native antigen was stereoselective consistent with the involvement of a cannabinoid (CB) receptor. Bioactive CP-55,940 diminished T cell activation, whereas the inactive stereoisomer CP-56,667 did not. The macrophage hybridoma expressed mRNA for the CB2 but not the CB1 receptor whereas the T cells expressed an extremely low level of mRNA for the CB2 receptor. The CB1-selective antagonist SR141716A did not reverse the suppression caused by THC, demonstrating that the CB1 receptor was not responsible for the drug's inhibitory effect. In contrast, the CB2-selective antagonist SR144528 completely blocked THC's suppression of the T cell response, implicating the participation of the CB2 receptor. These findings suggest that the CB2 receptor may be involved in CB inhibition of antigen processing by macrophages in this system.

0022-3565/99/2893-1620$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
A. E. B. Springs, P. W. F. Karmaus, R. B. Crawford, B. L. F. Kaplan, and N. E. Kaminski
Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by {Delta}9-tetrahydrocannabinol
J. Leukoc. Biol., December 1, 2008; 84(6): 1574 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. P. Buchweitz, P. W. F. Karmaus, K. J. Williams, J. R. Harkema, and N. E. Kaminski
Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of {Delta}9-tetrahydrocannabinol
J. Leukoc. Biol., March 1, 2008; 83(3): 785 - 796.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. A. Lunn, J. S. Fine, A. Rojas-Triana, J. V. Jackson, X. Fan, T. T. Kung, W. Gonsiorek, M. A. Schwarz, B. Lavey, J. A. Kozlowski, et al.
A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 780 - 788.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. A. Cabral and F. Marciano-Cabral
Cannabinoid receptors in microglia of the central nervous system: immune functional relevance
J. Leukoc. Biol., December 1, 2005; 78(6): 1192 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti
{Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response
J. Immunol., March 15, 2005; 174(6): 3281 - 3289.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. E. Rockwell and N. E. Kaminski
A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 683 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Oka, S. Ikeda, S. Kishimoto, M. Gokoh, S. Yanagimoto, K. Waku, and T. Sugiura
2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils
J. Leukoc. Biol., November 1, 2004; 76(5): 1002 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. L. F. Kaplan, C. E. Rockwell, and N. E. Kaminski
Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1077 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Arevalo-Martin, J. M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
J. Neurosci., April 1, 2003; 23(7): 2511 - 2516.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. J. McKallip, C. Lombard, B. R. Martin, M. Nagarkatti, and P. S. Nagarkatti
Delta 9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 451 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al.
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Alberich Jorda, S. E. Verbakel, P. J. M. Valk, Y. V. Vankan-Berkhoudt, M. Maccarrone, A. Finazzi-Agro, B. Lowenberg, and R. Delwel
Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol
Blood, April 15, 2002; 99(8): 2786 - 2793.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett
{Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway
J. Immunol., July 1, 2000; 165(1): 373 - 380.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Sugiura, S. Kondo, S. Kishimoto, T. Miyashita, S. Nakane, T. Kodaka, Y. Suhara, H. Takayama, and K. Waku
Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor. COMPARISON OF THE AGONISTIC ACTIVITIES OF VARIOUS CANNABINOID RECEPTOR LIGANDS IN HL-60 CELLS
J. Biol. Chem., January 7, 2000; 275(1): 605 - 612.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.